The pharmaceutical industry of India had a phenomenal month in November where it saw a 9% year-on-year growth driven by a surge in prices and the launch of new products.
Fresh data from data from AIOCD-AWACS indicates robust growth for the sector, which has been a key industry in India’s growth story.
Fantastic Figures for the Indian Pharma Sector
Every segment of the industry barring two saw impressive growth. Derma received an amazing 15.8% growth followed by Cardiac at 11.7%. Gastro and Anti-diabetic saw 11% & 10.1% growth respectively. Volume grew 1.8% in November 2024 as opposed to negative 4.5% a year back. Prices too grew at an increased pace this year. These figures paint an optimistic picture for the industry in the short to medium term. New launches increased 2.7%, and the same has been cited as a key catalyst for the growth in the pharmaceutical industry.
Continue Exploring: Sleep-deprived CEO: Wakefit’s #Gaddagiri campaign targets Zomato’s Deepinder Goyal
The best performers and the weakest firms
At the topmost spot Alkem Laboratories Limited, registered an impressive growth figure of 15.9%, propelling it at the top of the pack. Next, Glenmark Pharmaceuticals Limited also turned out fantastic figures at 15%. On the other hand, Dr Reddy’s Laboratories Limited boasted a 12.5% rate of growth. Abbott India and Sun Pharmaceuticals also performed above the industry average and returned great figures. While several other firms returned figures that were around the industry average.
Continue Exploring: OreGin: India’s first Kinnow-based Gin expands market reach
However, there were several firms that underperformed the industry average and returned disappointing figures. These included: Cipla Ltd. which saw a dip with a growth of 8.2%, while Lupin Ltd. followed closely at 8.1%, and Zydus Lifesciences Ltd. lagged behind with 5.9%. Other companies like Emcure (1.1%), Pfizer India (5%), Sanofi India (3.5%), JB Chemicals (6.6%), and Indoco Remedies (7%) also reported weaker growth compared to the overall average.